Rameda to bring Merck anti-covid pill to Egypt this quarter
Rameda to launch generic form of Merck’s covid pill: Rameda Pharma will begin selling its own generic version of Merck’s oral antiviral covid-19 med, Molnupiravir Rameda, before the end of 1Q2022, the company announced in an EGX disclosure (pdf). The company has begun manufacturing the pill after receiving authorization from the EDA, the national meds regulator. Molnupiravir Rameda will retail at EGP 625 per 40 capsules with an initial dose of 200 mg, with an eye to launch other, stronger versions of the pill “in due course,” the company said.
A total of five Egyptian companies are lining up to produce new covid meds and are waiting on the approval from the EDA, Health Ministry spokesperson Hossam Abdel Ghaffar said on Salat Tahrir yesterday (watch, runtime: 1:03:31).
The Health Ministry reported 1,232 new covid-19 infections yesterday, up from 1,197 the day before. Egypt has now disclosed a total of 401,308 confirmed cases of covid-19. The ministry also reported 31 new deaths, bringing the country’s total death toll to 22,179.